XML 51 R34.htm IDEA: XBRL DOCUMENT
v3.23.3

Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Jun. 30, 2023 USD ($) Program shares | May 31, 2023 USD ($) Program | Oct. 31, 2022 | Sep. 30, 2023 USD ($) $ / shares | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) $ / shares | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) Program shares | Dec. 31, 2020 USD ($) shares
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Common stock share value |  |  |  | $ 5,000,000 |  |  |  |  |
Amended Investor Rights Agreement |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Lockup period |  |  | 2 years |  |  |  |  |  |
Extended lockup period |  |  | 3 years |  |  |  |  |  |
Gilead Collaboration Agreement |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Option payment upon completion of certain IND-enabling activities |  |  |  |  |  |  |  | $ 60,000,000 |
Option payment upon achievement of certain development milestones |  |  |  |  |  |  |  | $ 150,000,000 |
Amended Gilead Collaboration Agreement |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Number of exercise option to programs | Program |  |  |  |  |  |  |  | 3 |
Option payments received |  |  |  |  |  |  |  | $ 725,000,000 |
Removal of option continuation payment under agreement |  |  |  |  |  |  |  | $ 100,000,000 |
Option payment upon achievement of certain development milestones |  | $ 150,000,000 |  |  |  |  |  |  |
Number of programs, eligible to receive regulatory and commercial milestone payments | Program |  | 2 |  |  |  |  |  |  |
Related Party |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Percentage of outstanding common stock held |  |  |  | 19.80% |  | 19.80% |  |  |
Related Party | Research and Development |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Reimbursement from related party for shared costs |  |  |  | $ 22,000,000 | $ 27,000,000 | $ 89,000,000 | $ 93,000,000 |  |
Related Party | Purchase Agreement |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Issuance of common stock (in shares) | shares | 1.0 |  |  |  |  |  |  | 5.7 | 6.0
Funds received for stock purchase agreement |  |  |  |  |  |  |  |  | $ 200,000,000
Purchase price of common stock allocation to performance obligation |  |  |  |  |  |  |  |  | $ 91,000,000
Common stock share value | $ 20,000,000 |  |  |  |  |  |  | $ 220,000,000 |
Percentage of premium purchase price of common stock |  |  |  |  |  | 20.00% |  |  |
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares |  |  |  | $ 33.54 |  | $ 33.54 |  |  |
Trailing days average closing price |  |  |  |  |  | 5 days |  |  |
Related Party | Purchase Agreement | Maximum |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Right to purchase additional outstanding voting common stock percentage |  |  |  | 35.00% |  | 35.00% |  |  |
Related Party | Gilead Collaboration Agreement |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Collaboration term for current and future clinical programs |  |  |  |  |  |  |  |  | 10 years
Option continuation payment due upon sixth anniversary of agreement |  |  |  |  |  |  |  |  | $ 100,000,000
Upfront cash payment |  |  |  |  |  |  |  |  | $ 175,000,000
Option fee per program for all other programs entering clinical development to exercise option |  |  |  |  |  |  |  | $ 150,000,000 |
Number of research programs |  |  |  |  |  |  |  | 2 |
Revenue recognized |  |  |  | $ 28,000,000 | $ 31,000,000 | $ 82,000,000 | $ 73,000,000 |  |
Related Party | Gilead Collaboration Agreement | Maximum |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Potential regulatory approval milestones payment receivable related to domvanalimab |  |  |  |  |  |  |  | $ 500,000,000 |
Related Party | Amended Gilead Collaboration Agreement |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Upfront cash payment | $ 35,000,000 | $ 17,500,000 |  |  |  |  |  |  |
Number of research programs | Program | 2 |  |  |  |  |  |  |  |
Option payment upon completion of certain IND-enabling activities |  | 45,000,000 |  |  |  |  |  |  |
Related Party | Amended Gilead Collaboration Agreement | Maximum |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |
Regulatory and commercial milestone payments received |  | $ 375,000,000 |  |  |  |  |  |  |

X
- Definition Collaboration term for current and future clinical programs. + References No definition available. + Details
Name: | rcus_CollaborationTermForCurrentAndFutureClinicalPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended lockup period. + References No definition available. + Details
Name: | rcus_ExtendedLockupPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Funds received for stock purchase agreement. + References No definition available. + Details
Name: | rcus_FundsReceivedForStockPurchaseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Lockup period. + References No definition available. + Details
Name: | rcus_LockupPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of exercise option to programs. + References No definition available. + Details
Name: | rcus_NumberOfExerciseOptionToPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs, eligible to receive regulatory and commercial milestone payments. + References No definition available. + Details
Name: | rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of research programs. + References No definition available. + Details
Name: | rcus_NumberOfResearchPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option continuation payment due upon Sixth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option fee per program for all other programs entering clinical development to exercise option. + References No definition available. + Details
Name: | rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option payment received. + References No definition available. + Details
Name: | rcus_OptionPaymentReceived
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option payment upon achievement of certain development milestones. + References No definition available. + Details
Name: | rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option payment upon completion of certain IND-enabling activities. + References No definition available. + Details
Name: | rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of outstanding common stock owned. + References No definition available. + Details
Name: | rcus_PercentageOfOutstandingCommonStockOwned
Namespace Prefix: | rcus_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of premium purchase price of common stock. + References No definition available. + Details
Name: | rcus_PercentageOfPremiumPurchasePriceOfCommonStock
Namespace Prefix: | rcus_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential regulatory approval milestones payment receivable related to domvanalimab. + References No definition available. + Details
Name: | rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Regulatory and commercial milestone payments received. + References No definition available. + Details
Name: | rcus_RegulatoryAndCommercialMilestonePaymentsReceived
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Related party transaction reimbursement from related party for shared costs. + References No definition available. + Details
Name: | rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Remove option continuation payment under agreement. + References No definition available. + Details
Name: | rcus_RemoveOptionContinuationPaymentUnderAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Right to purchase additional outstanding voting common stock percentage. + References No definition available. + Details
Name: | rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage
Namespace Prefix: | rcus_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation. + References No definition available. + Details
Name: | rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Trailing days average closing price. + References No definition available. + Details
Name: | rcus_TrailingDaysAverageClosingPrice
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | rcus_UpfrontCashPayment
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_AmendedInvestorRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |